Please note: The Research + Innovation office will be closed for the holidays from noon on December 24 through January 2nd, inclusive. 鉂勶笍 Veuillez noter que le bureau de la Recherche et de l'Innovation sera ferm茅 pour les vacances du 24聽d茅cembre 脿 midi jusqu鈥檃u 2聽janvier inclus.
Event
"Getting close to curbing the HCV pandemic": A Lecture by Nobel Prize Laureate Michael Houghton
Research and聽Innovation invites you to an exclusive opportunity to watch聽a聽Nobel Prize Laureate speak聽from an otherwise private summit.
顿谤.听, Li聽Ka聽Shing聽Professor of Virology at the聽University of Alberta, Canada Excellence Research Chair (CERC) Laureate in Virology聽(2010-2017),聽and聽2020 Nobel Prize Laureate, will聽deliver a lecture at the聽CERC/C150 Research Chairs 2021 Virtual Symposium.
One of the world's top scientists, Dr. Houghton was awarded the 2020 Nobel Prize in Physiology or Medicine聽in recognition of his discovery of the hepatitis C (HCV) virus. The聽discovery he made along with聽two of his colleagues聽in聽1989 opened a new field of viral hepatitis research that led to improved blood safety聽and groundbreaking聽HCV treatment.聽HCV is now the first chronic聽viral illness that聽can聽be cured in virtually all patients.
Dr. Houghton's lecture, "Getting close to curbing the HCV pandemic," will be publicly聽streamed on YouTube on June 8, 2021 at 12:00 p.m. EDT.聽
*No registration required. The link to the YouTube stream will be posted to this page on June 9.*聽
About Dr. Houghton
Dr. Houghton is an international leader in viral hepatitis. In 1989, his USA laboratory and聽collaborators identified the hepatitis C virus (HCV). He then developed blood tests that have since prevented millions of infections from tainted blood donations around the world. He also has over 40 years of experience in major pharmaceutical companies (Searle, Chiron, Novartis). His work at Chiron Corporation was largely responsible for its growth into the third largest USA biotech firm in the 1990s, ultimately being acquired by Novartis in 2005.
Along with Dr. Lorne Tyrrell and a team of experts, Dr. Houghton is developing a vaccine against hepatitis C (HCV) through the optimization of both the production of cross-neutralizing antibodies and cross-reactive immune responses to the different HCV genotypes found among聽the human population worldwide.聽
Dr. Houghton has authored more than 300 research publications and over 70 patents. He has received numerous international prizes for his scientific contributions, including the Robert Koch Medal (1993),聽the Clinical Lasker Award (2000), and the Canadian CLF-CASL gold medal (2012). His passion is the application of biomedical research to prevent disease.